A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Endometrial Carcinoma
A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma
An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease
A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis
A Phase 1b dose escalation study with a Phase 2a expansion component to evaluate the safety and tolerability of ETC 1907206 in combination with dasatinib in advance hematologic malignancies
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma